- Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
- Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
- Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
- First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments
- FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET
- FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET
- Flag Stockholders: Reminder to Vote for Proposed Business Combination
- First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
More ▼
Key statistics
As of last trade, Calidi Biotherapeutics Inc (CLDI:ASQ) traded at 1.70, 20.23% above the 52 week low of 1.41 set on Jul 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.63 |
---|---|
High | 1.89 |
Low | 1.58 |
Bid | 1.65 |
Offer | 1.76 |
Previous close | 1.70 |
Average volume | 523.03k |
---|---|
Shares outstanding | 6.42m |
Free float | 4.40m |
P/E (TTM) | -- |
Market cap | 10.91m USD |
EPS (TTM) | -6.76 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 21:10 BST.
More ▼